Antibody-based delivery of interleukin-9 to neovascular structures: Therapeutic evaluation in cancer and arthritis
- 21 January 2021
- journal article
- research article
- Published by Frontiers Media SA in Experimental Biology and Medicine
- Vol. 246 (8) , 940-951
Abstract
Interleukin-9 is a cytokine with multiple functions, including the ability to activate group 2 innate lymphoid cells, which has been postulated to be therapeutically active in mouse models of arthritis. Similarly, interleukin-9 has been suggested to play an important role in tumor immunity. Here, we describe the cloning, expression, and characterization of three fusion proteins based on murine interleukin-9 and the F8 antibody, specific to the alternatively spliced EDA domain of fibronectin. EDA is strongly expressed in cancer and in various arthritic conditions, while being undetectable in the majority of healthy organs. Interleukin-9-based fusion proteins with an irrelevant antibody specific to hen egg lysozyme served as negative control in our study. The fusion proteins were characterized by quantitative biodistribution analysis in tumor-bearing mice using radioiodinated protein preparations. The highest tumor uptake and best tumor:organ ratios were observed for a format, in which the interleukin-9 moiety was flanked by two units of the F8 antibody in single-chain Fv format. Biological activity of interleukin-9 was retained when the payload was fused to antibodies. However, the targeted delivery of interleukin-9 to the disease site resulted in a modest anti-tumor activity in three different murine models of cancer (K1735M2, CT26, and F9), while no therapeutic benefit was observed in a collagen induced model of arthritis. Collectively, these results confirm the possibility to deliver interleukin-9 to the site of disease but cast doubts about the alleged therapeutic activity of this cytokine in cancer and arthritis, which has been postulated in previous publications.Keywords
All Related Versions
Funding Information
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_182003/1)
- Horizon 2020 Framework Programme (670603)
- Swiss Federal Institute of Technology Zurich
This publication has 61 references indexed in Scilit:
- Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid LeukemiaScience Translational Medicine, 2013
- Th9 cells promote antitumor immune responses in vivoJournal of Clinical Investigation, 2012
- A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancerHead & Neck Oncology, 2011
- A Brief History of IL-9The Journal of Immunology, 2011
- Cellular sources and immune functions of interleukin-9Nature Reviews Immunology, 2010
- Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodiesAtherosclerosis, 2010
- Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritisArthritis Research & Therapy, 2009
- Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2Blood, 2009
- Ligand‐Based Vascular Targeting of DiseaseChemMedChem, 2006
- Engineered vascular‐targeting antibody‐interferon‐γ fusion protein for cancer therapyInternational Journal of Cancer, 2005